GT20029 Phase II Clinical Trial for Treatment of ACNE in China Completed First Subject Enrollment

KX-826 Received The INCI Designation

KX-826 Tincture 1.0% Clinical Trial For The Treatment Of Male Adult AGA In China Received Clearance By NMPA

GT20029 Phase II Clinical Trial for Treatment of AGA in China Reached Primary Endpoint

KX-826 Phase Ib/III Clinical Trial of Combination Therapy with Minoxidil For The Treatment of Male AGA Received Clearance by China NMPA

KX-826 Phase III Clinical Trial for Treatment of Male AGA in China Completed

KX-826 Phase III Long-term Safety Clinical Trial in China Completed Patient Enrollment

GT1708 Obtained Conditional Approval to Conduct Phase II Clinical Trial in China by NMPA for IPF

KX-826 Phase II Clinical Trial for Treatment of Male AGA in the U.S. Completed

GT1708 Phase I Clinical Trial for Treatment of Hematologic Malignancies in China Completed

Enrolment completed in Chinese phase III clinical trial of Fruetane for male pattern baldness

GT20029 U.S. Phase I Clinical Trial Completed

Kintor Pharma Completed Top-up Placing 2022-II, the Proceeds Received by the Company was Approximately HK$509.1 million

Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met

Kintor Pharma Announces Completion of Phase I Clinical Trial of GT20029 in China

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China

Kintor Pharma Completed Top-up Placing 2022-I, the Proceeds Received by the Company was Approximately HK$273.0 million

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Kintor Pharma and Etana's Collaboration on Pruxelutamide's COVID-19 Project Awarded with Belt and Road Innovation Project and Fund Support from the Science and Technology Department of Jiangsu Province

Pivotal data results from phase III global multicentre clinical trial of procainamide for the treatment of mild to moderate ambulatory new crown patients announced

Subject Enrolment Completed in Chinese Phase II Clinical Trial of Fruetane for Female Hair Loss

Kintor Pharma Announces First Patient Dosing of Phase III Clinical Trial of KX-826 for Treating Androgenic Alopecia Patients in China

Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma

Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Androgenetic Alopecia Was Met

Kintor Pharma Collaborates with Etana to Commercialize Proxalutamide for Treatment of COVID-19 in Indonesia

Kintor Receives EUA for Proxalutamide for the Treatment of COVID-19 in Paraguay

Kintor Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne

Kintor Announced U.S. FDA Has Greenlighted Phase II Clinical Trial for Pyrilutamide to Treat Androgenetic Alopecia

Kintor Announced ANVISA and CONEP in Brazil Approved Proxalutamide's Pivotal Study of Treating COVID-19 Male Outpatients Sponsored by Kintor

Kintor Annouced Top-up Placement to Raise USD 150mn

Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19

Kintor Has Expanded Its Geographical Presence to Zhuhai

GT20029 IND Was Accepted by NMPA

Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA

SMO Antagonist Obtains Approval of Clinical Trial from FDA

GT1708F Obtains Approval of Clinical Trial from FDA

Kintor Pharmaceutical’s Suzhou Industrialisation Base Granted Approval of Pharmaceutical Production License

New Start For New Journey! Kintor Relocated To Suzhou R&D Center And Industrialization Base

Proxalutamide Starts Clinical Trial For The Treatment Of COVID-19 In Male Patients

Kintor Pharma Signed Clinical Trial Agreement For The Treatment Of COVID-19 With Proxalutamide

Officially listed on the Hong Kong Stock Exchange (Stock Code:9939.HK)

Kintor pharmaceutical and Sinopharm signed a strategic cooperation agreement

The GT1708F project has been approved for clinical trials in China

It has completed Series D investment of approximtely USD45 million

Suzhou Kintor and CMAB Biopharma Inc. established strategic cooperation for the development and production of ALK-1 monoclonal antibody

The GT0486 (Detorsertib tablets) project has been approved for clinical trials in China

A phase II clinical trials of GT90001 (ALK-1 antibody) combined with PD-1 for liver cancer has been launched in Taiwan

The Group has signed a technical agreement with Peking University to in-license its c-Myc inhibitor project

GT90001 (ALK-1 antibody) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period

GT90001 (ALK-1 antibody) has been granted clinical trials permission from Taiwan Food and Drug Administration of China

The Suzhou production and R&D base has officially launched

The phase III clinical trial of GT0918 (Proxalutamide tablets) combined with Abiraterone for prostate cancer has been launched in China

The key phase III clinical trial of GT0918 (Proxalutamide tablets) as monotherapy for prostate cancer has been launched in China

The KX-826 (Pyrilutamide) project has been approved for clinical trials of hair loss indications by China and the United States

Suzhou Kintor has signed a cooperation agreement with Pfizer on the ALK-1 antibody project, and has been granted the first global exclusive license by Pfizer for developing a new antibody drug against tumor

The Group has obtained Series C investment of approximately RMB288 million

The joint-stock company has been established, and its approval for listing on the National Equities Exchange and Quotations has been approved

GT0918 (Proxalutamide tablets) project has obtained clinical trials approval for breast cancer indications in China, and phase I/Ib clinical trials have been launched

GT0918 (Proxalutamide tablets) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period

The phase II clinical trials of GT0918 (Proxalutamide tablets) project for prostate cancer indications have been launched in China

Suzhou Kintor has signed a MAH cooperation agreement with TOT BIOPHARM on GT0918 (Proxalutamide tablets) project

The phase I/II clinical trials of GT0918 (Proxalutamide tablets) project for prostate cancer indications have been launched in the United States

The Group has obtained Series B investment of approximately USD10 million

The GT0918 (Proxalutamide tablets) project has obtained clinical trials permission for prostate cancer indications in China and the United States, and phase I clinical trials have been launched in China

The Group has obtained Series A investment of approximately RMB20 million

The IND application of the Group's first project, GT0918 (Proxalutamide tablets), has been submitted for prostate cancer indications

Suzhou Kintor has received angel investment from Legend Star and Oriza Holdings